Neogi SB, Devasenapathy N, Singh R, et al. - Through a multicentre, open-label, phase 3, randomized, controlled trial at four government medical colleges in India of 2,018 pregnant women, aged 18 years or older, at 20–28 weeks of gestation with a haemoglobin concentration of 5–8 g/dL, or at 29–32 weeks of gestation with a haemoglobin concentration of 5–9 g/dL, experts evaluated the safety and clinical efficiency of intravenous iron sucrose (intervention) compared with standard oral iron (control) therapy in the treatment of women with moderate-to-severe iron deficiency anaemia in pregnancy. Because of futility, the study was terminated. In pregnant women with moderate-to-severe anemia, inadequate evidence was there to explicate the efficiency of intravenous iron sucrose in decreasing clinical outcomes compared with standard oral iron therapy.